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Abstract
Mitochondria dysfunction and hypoxic microenvironment are hallmarks of cancer cell biology. Recently, many studies have
focused on isolation of brain cancer stem cells using CD133 expression. In this study, we investigated whether CD133
expression is regulated by bioenergetic stresses affecting mitochondrial functions in human glioma cells. First, we
determined that hypoxia induced a reversible up-regulation of CD133 expression. Second, mitochondrial dysfunction
through pharmacological inhibition of the Electron Transport Chain (ETC) produced an up-regulation of CD133 expression
that was inversely correlated with changes in mitochondrial membrane potential. Third, generation of stable glioma cells
depleted of mitochondrial DNA showed significant and stable increases in CD133 expression. These glioma cells, termed
rho
0 or r
0, are characterized by an exaggerated, uncoupled glycolytic phenotype and by constitutive and stable up-
regulation of CD133 through many cell passages. Moreover, these r
0 cells display the ability to form ‘‘tumor spheroids’’ in
serumless medium and are positive for CD133 and the neural progenitor cell marker, nestin. Under differentiating
conditions, r
0 cells expressed multi-lineage properties. Reversibility of CD133 expression was demonstrated by transfering
parental mitochondria to r
0 cells resulting in stable trans-mitochondrial ‘‘cybrid’’ clones. This study provides a novel
mechanistic insight about the regulation of CD133 by environmental conditions (hypoxia) and mitochondrial dysfunction
(genetic and chemical). Considering these new findings, the concept that CD133 is a marker of brain tumor stem cells may
need to be revised.
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Introduction
Mitochondria play a major role in many cellular processes
including energy production, apoptosis, and generation of free
radical species. We previously demonstrated that glioma cell lines
relied on mitochondrial energy for survival [1,2,3]. Moreover,
mitochondrial dysfunction has been linked to an up-regulation of
glycolysis, which in turn promotes tumor progression and invasion
in all cancers [4,5,6]. Brain tumor stem cells have been recently
identified and characterized [7,8,9,10,11]. In particular, a
discovery was made that an important cell marker, CD133, that
is expressed in non-malignant neural progenitor cells, is also
expressed by brain tumor stem cells [8,9,10,12,13,14]. CD133,
also known as prominin-1, is a member of a family of glycoproteins
composed of five transmembrane domains, two cytoplasmic loops,
two glycosylated extracellular domains, and a cytoplasmic C-
terminal domain [15,16,17]. To date, there are no known ligands,
no signaling mechanisms have been identified and the functional
significance of CD133 remains unknown. However, its localization
in membrane protusions, filopodia and lamellipodia of mouse
neuroepithelial stem cells [18] suggests a function in membrane
topology [19]. The cellular mechanisms involved in the regulation
of CD133 remain unknown.
Several lines of evidence suggest that cancer stem cells could play
an important role in the initiation, progression, and recurrence of
many types of cancer. Thus, it is important to understand how these
cells are regulated in the context of tumor progression and therapy.
One avenue is a possible common microenvironment and
bioenergetic pathway between cancer cells and human embryonic
stem (hES) cells. Subsequent to implantation and vascularization in
vivo, hES cells are in a hypoxic environment between 1 to 5% of
oxygen [20]. Under these conditions, they remain pluripotent.
Because hypoxic embryonic cells cannot produce adequate amounts
of ATP via mitochondrial oxidative phosphorylation (OxPhos), they
rely on anaerobic metabolism to produce ATP to meet their energy
requirements [21], just as many cancer cells do [1,6].
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3655In this study, we tested the hypothesis that mitochondrial
status plays a role in the regulation of the CD133 expression in
human glioma cell lines. To this end, we used three cellular
models: long term exposure to hypoxia, pharmacologic blockers
of the ETC and genetic depletion of mitochondrial DNA (r
0). In
all three cellular models, we observed that, regardless of the
means used to produce a glycolytic bioenergetic phenotype,
CD133 is profoundly up-regulated. Moreover, up-regulation of
CD133 expression by hypoxia is reversible upon re-oxygenation.
Genetic depletion of mitochondrial DNA (r
0 model) increased
CD133 cell surface expression in an irreversible manner and
yielded a human glioma model in which CD133 is constitutively
expressed. Transfer of mitochondria from parental U251 cells to
r
0 cells results in transmitochondrial cybrid clones that manifest
parental phenotype. These results strongly demonstrate that
mtDNA depletion is at least partly responsible for the CD133
expression.
Our findings, in combination with the uncertain role of CD133,
suggest that the use of CD133 expression as a marker for brain
tumor stem cells should be critically evaluated.
Results
Expression of CD133 increases in glioma cells maintained
under hypoxia
To assess the effect of hypoxia on expression of CD133, we
cultured U251MG human glioma cells in 1% oxygen for up to 3
days and compared them to cells maintained under standard
normoxic conditions (21% oxygen). Flow cytometric analysis
indicated that CD133 expression was not detectable above
background when these cells were exposed to 21% oxygen.
However, U251MG glioma cells cultured in 1% oxygen were
enriched in CD133
+ cells (Fig. 1A). Using immunostaining, we
confirmed that CD133 labeling was localized in the plasma
membrane (Fig. 1B). We then studied whether CD133 expression
can be maintained for several days under hypoxic conditions. Cells
were grown in 1% oxygen for 3 days, passaged twice and
maintained in 1% oxygen for an additional 3 days. Flow cytometry
analysis conducted daily during this time period revealed that 40–
60% of U251MG cells became labeled with CD133 antibody.
Moreover, when cells were returned in 21% oxygen (re-
Figure 1. Expression of CD133 in U251 glioma cells under hypoxia. A) Flow cytometry histogram of representative U251 cells, with the first
peak representing cells negative for CD133-phycoerythrin expression, and the second peak representing CD133 positive cells. Histogram of U251 in
21% oxygen (a) compared with 1% oxygen (b). Data are representative of five similar experiments. B) Immunofluorescence photographs of
representative U251 cells grown in 1% oxygen and processed with CD133 antibody (red). Cytoplasm and nucleus were stained with (1 mM)
MitoTrackerH (green) and DAPI (blue) respectively. Arrowhead showing one CD133-negative cell in the field. C) Time-dependent expression of CD133
in glioma cells under hypoxia and reoxygenation. Results are given as means 6 SD of 5 separate experiments. *** represent p,0.001.
doi:10.1371/journal.pone.0003655.g001
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normoxic levels over the next 3 days (Fig. 1C). These experiments
demonstrate that hypoxic conditions increased the CD133
expression by the majority of U251MG glioma cells that normally
express a low level of CD133, and that this event was reversible
upon re-oxygenation. These findings have been reproduced using
the D54MG glioma cell line (data not shown).
Rotenone treatment enriched CD133 positive glioma cells.
In a recent study, we described that glycolytic glioma cells are
resistant to blockers of the ETC, in particular rotenone, a complex I
(NADH dehydrogenase) blocker [1,2]. To determine whether
CD133 positive glioma cells became enriched in presence of
rotenone, we treated U251MG glioma cells with 1 mMr o t e n o n e
forupto3daysundernormoxicconditions.Flowcytometricanalysis
indicated that 37610 % of the cells became labeled with anti-
CD133 antibody (Fig. 2A). Induction of CD133 by rotenone was
dose-dependent (Fig. 2B). We analyzed the data by Spearman
correlation test and by linear regression. Increases in the CD133
positive population after rotenone exposure were significantly
correlated with decreases in theirmitochondrialmembrane potential
(DYm) (rs=0.82; p,0.0001) (Fig. 2C). These findings have been
corroborated using the D54MG glioma cell line (data not shown).
Expression of CD133 increases in mitochondrial DNA
depleted human glioma cells.
Numerous mtDNA-depleted cell lines (rho
0, r
0)h a v eb e e n
generated by long-term treatment with very low doses of ethidium
bromide [22,23,24] in order to study important mitochondrial defects
in OxPhos, calcium homeostasis alteration, reactive oxygen species
(ROS) productionandresistancetoapoptosis. In order totest whether
loss of mitochondrial function by mtDNA depletion would also up-
regulate appearance of CD133
+ glioma cells, we generated U251MG
mtDNA depleted cells, termed U251r
0. The mtDNA content from
U251MG cells cultured with or without EtBr wasmonitored routinely
by amplifyingtotalDNA. As shown inFigure 3A,cytochromeoxidase
subunits I (COX I) and II (COX II) which are encoded only in
mtDNA were barely amplified from the total DNA of the cells treated
with EtBr. In contrast, nuclear DNA encoded COX IV was equally
detected in both control and EtBr-treated cells, indicating that
Figure 2. Rotenone enriched the population of CD133 positive glioma cells. A) Time-dependent expression of CD133 in U251 glioma cells
exposed to 1 mM rotenone for up to 3 days. B) Dose-dependent regulation of CD133 positive cells. C) Relationship between percentage of CD133
positive cells and DYm. Data were analyzed by linear regression and p value were calculated using Spearman correlation test. Results are given as
means 6 SD of 5 separate experiments. ** represent p,0.001.
doi:10.1371/journal.pone.0003655.g002
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altering the nuclear DNA replication in U251MG cells.
After clonogenic selection under ethidium bromide, pyruvate,
uridine and 72 serial passages, total oxygen consumption and
glucose uptake were measured. Oxygen traces from a Clark
electrode showed a time-dependent decrease in oxygen concen-
tration for cell suspensions from r
0 and parental glioma cells.
However, r
0 glioma cells consumed significantly less oxygen than
the parental cell lines (p,0.005; student’s t test) in nmol/min/10
6
cells: 2.4660.6 versus 0.460.5 for U251 versus U251r
0 (Fig. 3B).
Mitochondrial membrane potential (DYm) and mitochondrial
mass were assayed by flow cytometry. Decreased incorporation of
Rhodamine 123 in r
0 compared to parental cells indicated that
mitochondrial function was indeed impaired. Total mitochondrial
content, as revealed by cardiolipin detection using nonyl acridine
orange, remained unchanged (Fig. 3C). These results indicated
that r
0 treatment perturbed mitochondrial function but did not
change the quantity of mitochondria. Concomitantly, glucose
uptake was significantly increased in U251r
0 compared to U251
(p,0.05; student’s t test), which we have shown as a glycolytic type
[1], has elevated glucose transporters and glucose uptake (Fig. 3D).
To determine whether CD133 expression was up-regulated in
r
0 glioma cells, we analyzed CD133 expression by flow cytometry.
Figure 4A illustrates that the CD133
+ glioma cell population
increased from 0.560.02% to 52.4067.54% for U251r
0 cells.
This increased level of CD133 expression remained stable for up
to 72 passages (data not shown). This finding raised the question of
whether expression of CD133 was due to transcription or post-
transcription mechanisms. RT-PCR revealed that CD133 mRNA
was expressed in both parental and r
0 glioma cells, suggesting that
expression of CD133 messenger does not predict cell surface
immunoreactivity with CD133 antibodies (Fig. 4B). It seems that
expression of the CD133 protein is at least partly regulated at a
post-transcriptional level. The relative levels of expression were
consistent with that reported for CD133 transcripts in retinoblas-
toma, lung and colon adenocarcinoma [25].
In order to test the potential oncogenic transformation of
mtDNA depleted cells, we performed anchorage-independent
growth in soft agar and Matrigel invasion assays. Soft-agar plating
efficiency was significantly increased in r
0 cells compared to the
parental glioma cells (p,0.001 for U251 versus U251r
0; Fig. 4C;
student’s t test). Matrigel invasion assays showed that U251r
0 are
significantly more invasive than the parental U251 cells (p,0.05;
student’s t test) (Fig. 4D). Taken together; these data indicated that
r
0 glioma model depleted of their OxPhos pathways have a more
aggressive transformed phenotype than their isogenic counterpart.
Essentially, identical findings have been observed with the
D54MG glioma cell line (data not shown).
U251r
0 glioma cells harbor properties ascribed to neural
and brain tumor stem cells
Previous studies described that brain tumor stem cells (BTSCs),
as well as their neural stem cell counterparts, are characterized by
their ability to form neurospheres in defined serum-free culture
medium supplemented with epidermal growth factor (EGF) and
basic fibroblast growth factor (bFGF) [26]. Moreover, cells
Figure 3. Bioenergetic characterization of mtDNA depleted U251 glioma cells. A) Genomic DNA was isolated from control and mtDNA-
depleted U251 cells, and mtDNA-encoded genes including cytochrome c oxidase subunit I (COX-I) and cytochrome c oxidase subunit II (COX-II) were
amplified by PCR. COX IV is used as a nuclear DNA-encoded control. The PCR products were electrophoresed on 1.5% agarose gel and then visualized
by EtBr staining. A representative result of three independent experiments is shown. B) Average oxygen consumption rates in U251 and U251r
0.
Results are given as means 6 SD of 5 separate experiments. C) Rhodamine123 fluorescence profiles of U251 and U251r
0; NAO fluorescent profiles of
U251 and U251r
0. D) Glucose transport activity for the parental and r
0 cells. Results are given as means 6 SD of 3 separate experiments.
doi:10.1371/journal.pone.0003655.g003
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(CD133), neural stem cell markers. Under differentiation condi-
tions, BTSCs expressed markers of neuronal and glial lineages
[7,8,9,10,11,13,27].
We used the culture conditions that favor neural stem cell
growth, previously established for isolation of neural stem cells as
neurospheres [26]. Neurobasal medium allows for the mainte-
nance of an undifferentiated stem cell state, and the addition of
bFGF and EGF induce proliferation of multipotent, self-renewing,
and expandable neural stem cells [9,10,26]. Within 48–72 h,
U251r
0 cultures yielded cells that demonstrated growth into
clonally-derived neurosphere-like clusters, which we termed tumor
spheroids (Fig. 5A, a). Under DMEM/F12 supplemented with 7%
fetal bovine serum, r
0 U251 grows adherently to the plastic
substrata and does not form tumor spheroids (Fig. 5A, b). Tumor
spheroids retained expression of the classical neural stem cell
markers CD133 and nestin (Fig. 5B, a-c, upper panels). We next
employed conditions used for neurosphere differentiation to
determine whether the U251r
0 were capable of multilineage
differentiation. After differentiation with 10% FBS for 7 days,
immunocytochemistry was performed on U251r
0 tumor spheroids
using antibodies for neuron-specific b III-tubulin and, astrocyte-
specific GFAP. As illustrated in Figure 5B, a-c, lower panels, cells
from U251r
0 tumor spheroids exhibited immunoreactivity for
both markers indicating multilineage properties.
Transmitochondrial cybrid cell lines shows parental
phenotype
In order to further demonstrate that up-regulation of CD133 is
a consequence of mtDNA depletion, we repaired the defect by
generating cybrid clones in which wild type parental (U251MG)
mtDNA was transferred to r
0 cells. Following the enucleation-
Figure 4. Anchorage-independent, invasion and CD133 expression in r
0 glioma cells. A) Flow cytometry determination of the percentage
of CD133 expressing parental and r
0 cells. Results are given as means 6 SD of 5 separate experiments. B) RT-PCR detection of CD133 mRNA from
U251 and U251r
0 glioma cells. Electrophoresis resolved amplicons for CD133 (0.4 kbp) and actin (0.2 kbp) of anticipated sizes. C) Colony formation in
soft agar. Results are given as means 6 SD of 3 separate experiments. D) Analysis of invasion into Matrigel 24 h after 5% FCS as chemo-attractant has
been added to the lower chamber. *, **, *** represent p,0.05, p,0.005 and p,0.001.
doi:10.1371/journal.pone.0003655.g004
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were isolated. We selected 2 of these cybrid clones for subsequent
analyses that by PCR showed repletion of the mitochondrial
encoded cytochrome oxidases COX I and COX II to normal
levels compared to U251MG cells. In contrast, nuclear-encoded
mitochondrial COX IV remained unchanged in U251MG
parental cells, in mtDNA depleted r
0 cells or in the cybrid cells
(Fig. 6A). These results indicated that r
0 cells were repopulated
with exogenous mtDNA from U251MG parental glioma cells
resulting in transmitochondrial cybrids.
To determine Dym after mtDNA repletion, we exposed living
cells to rhodamine 123 which is preferentially taken up by
mitochondria. Flow cytometric measurements revealed an increase
in Dym in both cybrid clones compared with r
0 cells. Compared
with U251MG, a 3861.73% and 4062.54% increase in average
fluorescent intensity incorporated into mitochondria was detected in
cybrid 1 and cybrid 3 respectively (P,0.005, Fig. 6B). Consonant
results were also obtained by flow cytometry with NAO-stained
U251MG, r
0 and cybrid cells. The average fluorescence emission in
r
0 cells was not markedly different from that in parental U251MG
cells. However, 1.97 and 2.84 fold-increases in NAO incorporation
were detected in cybrid 1 and cybrid 3, respectively, compared with
U251MG parental cells (P,0.05, Fig. 6C).
Figure 6D shows electron photomicrographs of parental
U251MG, r
0 and cybrid 1 cells. U251MG and cybrid 1 cells both
contained homogeneous, elongated mitochondria. In contrast, most
of the r
0 cells visualized appeared to have swollen or enlarged
mitochondria, showing either complete loss of cristae patterns with
empty mitochondrial structure or a disorganized cristae pattern.
Energy production of r
0 cells completely depends on anaerobic
glycolysis and it stands to reason that glucose consumption of
cybrid clones should be elevated. Reference values were obtained
by examination of U251MG cells, which we have previously
defined as largely, but not completely, glycolytic. Glucose
consumption (Fig. 6E) of r
0 cells (2562.7 pmol Glc/min/mg
protein), however, more than doubled the already increased rate
seen in parental U251MG glioma cells (1162.2 pmol Glc/min/
mg protein). However, after repairing the mtDNA loss, glucose
consumption by the cybrids decreased to values similar to that of
U251MG cells (661.5 and 1261.8 for cybrid 1 and cybrid 3
respectively). Additional evidence of the restoration of mtDNA is
the fact that the cybrid clones no longer required supplementation
with pyruvate and uridine for survival.
Cybrid cells derived from r
0 cell lines were stained with
fluorochrome-conjugated primary antibodies against CD133 and
were analyzed by flow cytometry. FACS analyses indicated that
CD133 was highly expressed in r
0 cells but after repair of these
mtDNA-depleted cells by fusion with U251MG cytoplasts, the
elevation in CD133 expression was reversed to parental U251MG
cell levels (Fig. 6F).
Discussion
Hypoxia is a hallmark of glioblastoma multiforme tumors and is
believed to promote cancer development, invasive dispersal of
tumor cells, and resistance to therapy [28,29,30]. Because oxygen
is the main substrate of the ETC, hypoxic conditions consequently
decreases mitochondrial function and initiates expression of a host
of genes that are needed for compensatory ATP production by
glycolysis. We showed that glioma cells from long-term established
cultures under ambient oxygen (21%) did not express CD133 until
they were transferred to severe hypoxia (1% Oxygen) and then
Figure 5. r
0 glioma cells form neurosphere-like tumor spheroids expressing neural stem cell markers, nestin and CD133. A) Phase
contrast microphotographs (magnification X20) of r
0 glioma forming (a) neurosphere-like structures in serumless Neurobasal medium supplement
with EGF and FGF after 10 days in culture or (b) adherent culture in DMEM/F12 medium with 7% FBS. B) Spheroids of r
0 cells were immunostained
with (b) CD133 or (c) Nestin antibodies or nuclear counterstained with Hoechst 33258 (a). C) Differentiation potential of r
0 tumor spheroids.
Multipotency was assayed by immunofluorescence for neuronal (bIII-tubulin) (a, c) and glial (GFAP) (b a, c) markers.
doi:10.1371/journal.pone.0003655.g005
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exposed to 1% O2. This CD133 expression on the cell surface was
immediate, transient and completely reversible when the cells were
returned to ambient oxygen conditions. It is well known that not
all tumor cells undergo hypoxia at a fixed time during the
formation of the tumor mass. Indeed, chaotic tumor angiogenesis
may lead to heterogeneous blood perfusion (blood vessels
regressing or collapsing). Thus, the supply of oxygen and/or
Figure 6. Characterization of U251 transmitochondrial cybrids. A) Genomic DNA was isolated from control, mtDNA-depleted and
transmitochondrial cybrid cells, and mtDNA-encoded genes including COX-I and COX-II were amplified by PCR. COX IV serves as a nuclear DNA-
encoded control. The PCR products were electrophoresed on 1.5% agarose gel and then visualized by EtBr staining. A representative result of three
independent experiments is shown. B) Representative histograms of R123 fluorescence for U251, U251r
0 and cybrids cells (left); average R123
fluorescence profiles (right). C) Representative histograms of NAO fluorescence for U251, U251r
0 and cybrids cells (left); average NAO fluorescence
profiles (right). D) A Representative electron transmission microscopy photographs comparing U251, U251r
0 and cybrids cells (Magnification X6000).
Arrowhead showing that U251r
0 cells have smaller mitochondria with large intramembraneous spaces. E) Glucose transport activity for the parental
and r
0 cells. Results are given as means 6 SD of 3 separate experiments. F) Representative histograms of flow cytometry CD133 fluorescence for
U251, U251r
0 and cybrids cells (left). Percentage of CD133 expressing cells (right). Results are given as means 6 SD of 5 separate experiments.
doi:10.1371/journal.pone.0003655.g006
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stem cell’’ marker such as CD133 could be transiently expressed as
part of the ‘‘glycolytic response’’.
It is possible that the low incidence of CD133-expressing cells
observed in many studies is related to supraphysiologically high
o x y g e nc o n d i t i o n so fr o u t i n et i s s u ec u l t u r e .I n d e e d ,w es h o w e dt h a t
under ambient oxygen less than 3% of U251MG cells expressed
CD133. Similarly, low percentages have been described for D54MG
[13] and U87MG [14] glioma cells. Two recent studies have
described an enriched CD133-positive cell fraction in cells exposed to
low oxygen concentration [27,32]. Therefore, oxygen tension
emerges as a main regulator of CD133 expression. Just as hypoxia
plays a major role in tumor development, a similar trend is observed
during embryogenesis [33,34,35]. Indeed, hypoxia is known to
maintain human embryonic stem cells (ES) in undifferentiated
phenotypes [20]. Upon return to normoxia, ES begin to differentiate.
Thus, hypoxia, leading to deprivation of the main electron
acceptor, causes perturbation of mitochondrial membrane potential
(Dy) and decreases the coupling efficiency between oxidation and
phosphorylation. We previously demonstrated that the presence in
the culturemediumof rotenone, an inhibitor ofthe respiratory chain
ComplexI,significantlydecreased Dy,without affecting cellviability
in U251MG glioma cells [2]. We have shown here that rotenone
caused a significant increase in CD133 expression by glioma cells,
and this effect was significantly correlated with the inhibition of the
mitochondrial membrane potential, demonstrating that mitochon-
drial function plays a crucial role in the regulation of CD133
expression. However, a definitive and specific role of Complex I in
CD133 regulation remains to be elucidated.
The importance of mitochondria in tumor biology has its roots
in Warburg’s original studies [4,36]. He postulated that the origin
of cancer was due to an irreversible damage of mitochondrial
function, leading to enhanced glycolysis. Many studies since then
have confirmed increased glycolytic capacity in many malignant
tissues, including glioma. However, other studies have demon-
strated that cancer cells have functional mitochondria [37,38].
Our previous study identified several glioma cell lines that were
dependent on mitochondrial OxPhos pathway while others were
largely dependent on glycolysis. Critically important, glycolytic
glioma cells were able to switch energy production to OxPhos in
order to survive under limiting glucose conditions, indicating that
dual bioenergetic capabilities [1,39,40] can be revealed using the
appropriate stressors. Thus, mitochondria of glycolytic glioma are
functional and essential for survival under low glucose conditions.
We initiated this study to investigate the possible link between
mitochondria function and tumor progression in human glioma. In
vitro, mammalian cells can be depleted of their mitochondrial
DNA, creating r
0 cells [22,24,41]. r
0 cells lack a functional
electron transport chain and appear incapable of generating ATP
via the OxPhos mitochondrial pathway. We generated r
0 glioma
models that are characterized by decreased O2 consumption,
decreased mitochondrial membrane potential and increased
glucose uptake. These cells are auxotrophic for uridine and
pyruvate and grow quite well without a functional ETC. We
showed that r
0 glioma cells developed enhanced anchorage-
independent growth and increased invasion phenotypes. These
enhanced tumorigenic properties of mtDNA-depleted glioma cells
is in accordance with studies reported in mtDNA-depleted human
pulmonary carcinoma cells and HeLa cells [12,42]. To our
knowledge, this is the first report of a r
0 model in human glioma.
One key feature of this model is the stable expression of CD133.
Indeed, the proportion of CD133-expressing cells remains
constant during more than 72 serial passages. Moreover, our
mtDNA-depleted glioma cells, when grown under defined
serumless medium, were able to form tumor spheroids that closely
resembled neurospheres that develop under identical conditions
from normal neural stem cells. Moreover, mtDNA-depleted
glioma cells displayed the capacity for long-term proliferation,
self- renewal, and multipotency. All of these properties are classical
features of neural stem cells [26] or brain tumor stem cells [7]. The
defects in respiratory function following induction of the mtDNA
depletion in r
0 glioma cells were reversed by repletion of mtDNA
with from enucleated U251MG cytoplasts. Restoration of
mitochondrial function in cybrid cells resulted in down-regulation
of CD133 expression to parental cell levels. This finding indicates
that mitochondrial encoded proteins and their associated functions
in the cells play a role in the expression of CD133.
Our data support a revised model of tumor progression, where
epigenetic factors play a critical determinant role [43]. In this tumor
progression model,the originof the first transformed cellisirrelevant
but focuses on adaptive biological processes induced in tumor cells
through genetic or mitochondrial mutations [44]. This model places
a stronger emphasis on the effect of the microenvironment, which is
universally recognized has one of the main driving forces of tumor
progression [6,45,46] (Fig. 7). Our model considers the following
factors: (a): nascent tumor cells begin to divide until they have
produced nutrient and oxygen diffusion barriers [6]. These cells
encounter stringent growth limitation through lack of oxygen and
nutrients. A significant fraction of these cells that are close to the
most stringent hypoxic microenvironment will have a significant loss
of mitochondrial OxPhos function and subsequently switch to
glycolysis. This glycolytic switch will trigger expression of stem cell
markers such as CD133 and multiple phenotypic changes that result
in increased invasion, migration and angiogenesis. (b): increased
angiogenesis willresult information of new vessels that will provide a
transient increase in the microenvironment content of oxygen and
nutrients allowing the switch from glycolysis back to OxPhos
metabolism.(c):becausethecellsatthemarginoftumorinvasionwill
be re-oxygenated, they will grow and divide generating a new
oxygen and nutrient diffusion barrier. (d): many such cycles of
growth and angiogenesis are repeated during the progression of the
tumor. In this model, a feature of the bioenergetically stressed
phenotype of glioma cells, as defined by the microenvironment, is
expression of CD133. Thus, the number of CD133-positive cells
fluctuates, adding a dynamic and transitory dimension to the
progression of the tumor.
Another feature of this microenvironment driven phenotype
accommodation that validates this model, is the capacity of glioma
cells to switch bioenergetic pathways as has been demonstrated by
our group and others [1,2,40,47,48]. Glioma cells that constitute
the bulk of the progressively growing tumor need be extremely
plastic, resistant to cell death in unfavorable growth conditions,
but most at all, opportunistic of their environment, as has been
suggested [49]. Glioma cells with this capability represent a
functionally unique subpopulation of cancer cells that manifest
‘‘cancer stem cell’’ properties. The difficulty in designing more
efficient therapies lies in understanding how these subpopulations
of cells respond to these microenvironmental challenges by
engaging different survival pathways.
A critically important observation from our study is that
metabolic flexibility is necessary and essential for tumor progres-
sion in glioma. Induction of two opposing phenotypes in cells of
identical genetic background demonstrates the plasticity, multi-
potency and opportunistic properties of these tumors. It suggests
that malignant glioma cells are capable of adapting to and
remodeling their microenvironment, switching phenotypic behav-
ior to improve their chances for survival. We understand the
outcome of becoming more invasive to move to a more hospitable
CD133 and Bioenergetic Stress
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cell markers, nestin and CD133, as survival attributes is less clear.
We described here that hypoxia and modification of the
bioenergetic status of glioma cells govern the regulation of CD133
at post-transcriptional level. Data presented here strongly
indicated that changes in the cellular environment that results in
alteration of mitochondrial function are responsible for the
enhanced up-regulation of CD133 antigen in glioma cells,
suggesting that CD133 expression in human glioma cells is not
obligatory relative to the stem cell phenotype but rather, reveals
the occurrence of a stress response.
Materials and Methods
Cell and culture and hypoxia treatment
Human glioma cell lines U251-MG and D54-MG were
originally obtained from Dr. D.D. Bigner (Duke University,
Durham, NC). Parental U251-MG and D54-MG cells were
cultured using 50:50 mixture of DMEM and Ham’s nutrient
mixture F12 (MediaTech) supplemented with 7% heat- inactivated
fetal bovine serum (HyClone) and 2.6 mmol/L L-glutamine. Cells
were treated with in-vitro hypoxia for up to 7 days at 1% O2 in a
hypoxia chamber (Coy, Laboratory). For re-oxygenation experi-
ments, cells were returned to 21 % O2 for the designated period of
time. All chemicals were purchased from Sigma Chemical Co. (St.
Louis, MO), unless otherwise stated.
Staining of mitochondria
Glioma cells were plated in 12-well plates and cultured for 24 h.
Cell monolayers were harvested using trypsin-EDTA (Gibco),
washed with Dulbecco’s PBS and stained with mitochondrial
fluorescent dyes 10-N-nonyl-Acridin Orange (NAO, 1 mM) or
Rhodamine 123 (R123, 5 mM) for flow cytometric analysis. After
15 min at 37uC, samples were washed once with 2% FCS/PBS to
remove unbound dyes, resuspended in 2% FCS/PBS with 2 mg/
ml of propidium iodide to allow exclusion of dead cells by FACS.
Flow cytometry was performed using a FACSCalibur (Becton
Dickinson) and analyzed with FlowJo software (Tree Star, Inc.).
Each analysis included at least 20,000 events.
Flow cytometric analysis for CD133
Glioma cells were incubated in cell staining buffer containing
biotin-conjugated anti-AC133/1 antibody (Miltenyi Biotec) fol-
lowed by incubation with Streptavidin-APC-Cy5.5. Isotype-
matched immunoglobulin served as controls. Cells were incubated
for 20 min at each step and were washed with 2% FCS/PBS
between steps. After staining, cells were resuspended in 2% FCS/
PBS with 2 mg/ml of propidium iodide to identify dead cells. Two-
color flow cytometric analyses were performed using a FACSca-
libur (Becton Dickinson) and FlowJo software (Tree Star, Inc).
Each analysis included at least 25,000 events. The percentage of
CD133
+ cells present was assessed after correction for the
percentage of cells reactive with an isotype control.
Immunocytochemical staining of CD133 glioma cells
Cells were cultured on 12 mm poly-lysine coated glass cover
slides. After treatment, cells were incubated in staining buffer
containing biotin-conjugated anti-AC133/1 antibody (Miltenyi
Biotec) followed by incubation with Alexa Fluor 555 streptavidin.
Cells were incubated for 20 min at each step and were washed with
2% FCS/PBS between steps. After staining cells were fixed with 4%
paraformaldehyde (15 min, room temp) and rinsed 3 times with D-
PBS. Cells were nuclear counterstained with 496-diamidino-2-
phyenylindole (DAPI), washed and mounted in Fluormount G
(Southern Biotechnology Associates) and viewed with a Leica/Leitz
DMRB fluorescence microscope equipped with appropriate excita-
tion and emission filter sets (Chromatechnology). Images were
acquired with a C5810 series digital color camera (Hamamatsu
Photonic System). Images were processed with Adobe Photo Shop
and IP LAB Spectrum software (Signal Analytics Software).
Reverse Transcription-Polymerase Chain Reaction
Analysis of CD133
Total RNA was extracted using RNeasy Micro Kit (Qiagen).
Reverse transcriptase polymerase chain reaction (RT-PCR) was
performed on cDNA using primers specific for CD133 and actin
as previously described [38]. PCR products were run on 2%
agarose gel with ethidium bromide and visualized using the Eagle
Eye Gel reader (Stratagene).
Generation of mtDNA depleted glioma cells (r
0 cells)
U251-MG and D54-MG cells were cultured in 50 ng/ml
Ethidium bromide in DMEM/F12 supplemented with 7% FBS,
1 mmol/L pyruvate and 50 mg/ml uridine. Cells were seeded at
low density onto 6 well plates and individual colonies propagated
Figure 7. Tumor progression model: (a) Initiation of tumor formation. (b) Tumor growth restricted at the oxygen and glucose diffusion barrier. (c)
Glioma ells at the edge of the tumor will be re-oxygenated by neovascularization, and grow and divide until they reach a new oxygen and nutrient
diffusion barrier. (d): repetitive cycles of growth and angiogenesis occur during the progression of the tumor.
doi:10.1371/journal.pone.0003655.g007
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passage twice a week and medium changed every other day.
Oxygen Consumption Measurements
Cells from triplicate cultures were trypsinized and suspended at
1610
6 cells/ml in DMEM/ F12 supplemented with 7% FBS.
Oxygen consumption was measured in a 1-ml volume gas-tight
vessel thermostatted at 37uC, equipped with a Clark type oxygen
electrode (Hansatech Instrument Ltd) as described [50]. The data
were exported to a computerized chart recorder (Oxygraph 1.01,
Hansatech, Instrument Ltd), which calculated the rate of oxygen
consumption expressed as nmol oxygen consumed/min/10
6 cells.
Carbonyl cyanide methoxy phenylhydrasone (FCCP), a mito-
chondrial uncoupler was used to assay maximal oxygen consump-
tion rate.
14C-2-deoxy-D-glucose (DOG) uptake
14[C]-DOG was purchased from Amersham Biosciences (Piscat-
away, NJ) (61 mCi/mmol). Uptake experiments were carried out
as we have described previously [1].
Anchorage independent clonogenic assay
Glioma cells (2,000) previously mixed with 0.45% agar-
DMEM/F12 supplemented with 7% fetal bovine serum were
seeded on a 0.9% agar cushion. Cells were fed every 5 days with
DMEM/F12. After 3 weeks, the colonies were fixed with PBS-
formalin, stained with Giemsa and counted.
In vitro invasion assay
Cell invasion assays were conducted in BD BioCoat matrigel
invasion transwell chambers with 8.0-mm pore membranes (BD
Biosciences). Cells (4610
4) in 500 mL culture medium were added
to the upper chamber. The bottom chambers contained 800 mL
culture medium supplemented with 7% FCS as a chemoattractant.
At 24 h later, the upper membranes were wiped with cotton swabs
and any cells that had migrated to the bottom side of the
membranes were fixed in ice-cold methanol. Hematoxylin and
eosin staining was performed and membranes were excised, placed
on microscope slides. Cells in five random visual fields (1006
magnification) were counted for each membrane. All experiments
were done in triplicates.
Transmitochondrial cybrid generation
To obtain transmitochondrial cybrids, human U251MG glioma
cells were enucleated as previously described [51,52]. Briefly, cells
were treated with cytochalasin B (10 mg/ml) and then layered on a
Ficoll step gradient. After centrifugation at 37uC for 90 minutes at
130,000 g cytoplasmic fractions were collected. The cytoplasts
were then fused with U251 r
0 cells by adding a solution of 50%
polyethylene glycol (MW 1450, Sigma cat P-5402) in phosphate
buffer. Cybrids were plated and continuously grown in DMEM/
F12 medium supplemented with 7% dialyzed FBS. Two weeks
after fusion, cybrids were plated at low density for clonogenic
selection.
Transmission electron microscopy
Electron photomicrographs for parental U251MG, U251 r0
and transmitochondrial cybrid cells were prepared as described
previously [53]. Briefly, cell pellets were washed in sucrose/
phosphate buffer and fixed in paraldehyde and glutaraldehyde.
Pellets were then post-fixed in phosphate-buffered 1% osmium
tetroxide. Samples were stained en bloc with 2% uranyl acetate,
rinsed, dehydrated, and embedded in Spurr’s resin. Thin sections
were cut on an Ultracut E ultramicrotome (Reichert-Jung), placed
on copper grids, stained with lead citrate, and micrographed with
an EM-1200 EX II electron microscope.
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